Clinical Trial Update: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study [Phase 3]

View source ↗

Summary

Phase 3 investigator-initiated randomized trial in EGFR-mutated non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Region Skane | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING